
Mainz Biomed Seeks FDA Breakthrough Status for Advanced Colorectal Cancer Test
Mainz Biomed has applied for FDA breakthrough device designation for its innovative colorectal cancer screening test, which combines traditional methods with mRNA biomarker analysis and AI algorithms to potentially revolutionize early detection.
Read full story



























